Skip to main content
. 2025 Jun 3;16:1585953. doi: 10.3389/fimmu.2025.1585953

Figure 2.

Figure 2

Specific staining and analysis of PtC-Specific B cells in pAPS using PtC liposomes. (A) Overlay of PtC-specific B cells stained with either CF594 labeled PtC liposomes, OG labeled liposomes, non-fluorescent control liposomes or without the addition of any liposomes (FMO). (B) Representative dot plot for the identification of PtC-specific B cells. Only B cells that are positive for both PtC-CF594 and PtC-OG were considered autoantigen-specific. (C) Two representative pseudocolor dot plots of PtC-specific B cells with a complete staining (left) and after blocking of specific binding-sites with non-fluorescent control liposomes (right). (D) Quantification of the relative decrease in PtC-specific B cells in 4 representative samples before- and after blocking with non-fluorescent control liposomes. (E) Frequencies of PtC-specific B cells and their distribution to major B cell subsets. B cell subsets were classified as in Figure 1 . (F) Frequencies of atypical PtC++CD21low and PtC++CD11chigh B cells among the cohorts. PtC, phosphatidylcholine; APS, antiphospholipid syndrome; pAPS, primary APS; sAPS, secondary APS; HC, healthy control; USM, unswitched memory; SM, switched memory; DN, double negative; OG, Oregon-Green. Statistics: Wilcoxon rank-sum testreference group: HC*p<0.05, **p<0.01, ****p<0.0001.